Infections

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

COVID-19

IgA Deficiency

Pneumonia

Pneumonia, Viral

Communicable Diseases

Respiratory Tract Infections

Virus Diseases

Coronavirus Infections

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Lung Diseases

Respiratory Tract Diseases

Anti-Infective Agents

All Drugs and Chemicals

Anti-Bacterial Agents

Antibiotics, Antitubercular

Immunosuppressive Agents

Immunoglobulin A

Anne-Sophie KORGANOW, MD, PhD

Olivier VOLLMER, MD

Jeanne MALLICK, MD

Isabelle JAHN

The management of patients with a selective IgA deficiency currently consists of symptomatic treatment with treatment of infections by occasional or prolonged antibiotic therapy, immunosuppressive treatments for autoimmune pathologies, symptomatic treatment of allergic manifestations.

IVIG supplements are sometimes proposed in the event of recurrent infections and the demonstration of deficiencies in IgG subclasses (IgG1, 2, 3) often not sought for diagnosis The factors associated with the severity of clinical manifestations are not well identified and patients with IgA deficiency must be monitored over the long term because of the risk of the appearance of autoimmune manifestations and neoplasia. The identification of such factors could lead to the proposal of close monitoring for these patients.

IgA deficiency, which is frequent, has not been identified as a risk factor for severe COVID-19 infection, probably due to a lack of studies with sufficient recruitment. The therapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19 infection is therefore not consensual.

There is currently no action to be taken regarding the risk of transmission of IgA deficiency.

Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission

Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission: A Retrospective Cohort Study in Strasbourg University Hospital

University Hospital, Strasbourg, France

Neoplasms

Autoimmune Diseases

Neoplasm Metastasis

Immunomodulating Agents

Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.

It will include:

* DNA samples collection
* RNA samples collection
* Blood sample collection

Biological collection

Jacques-Eric GOTTENBERG, MD, PhD

Bertrand MENNECIER, MD

This is a real life observational longitudinal study aiming to identify autoimmune manifestations in patients treated with "checkpoint inhibitors" in mono or combo therapy in real life.

The study is based on patients reported experience validated by physician, recruited in cancer centers in France with another data collection from a French healthcare data claims database and a biological collection.

Patient-Reported AutoImmunity Secondary to Cancer immunothErapy

Severe autoimmune manifestations is defined by :

* Discontinuation (temporary or definitive) of the cancer immunotherapy related to Autoimmunity
* or requirement for treatment due to auto-immune manifestations according to expert judgement
* or hospitalization for autoimmune manifestations
* or death related to autoimmune manifestations

Comparison of the age for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

Comparison of the gender for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

Comparison of the body-mass index for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

Comparison of the types of cancer for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

Comparison of the number of previous lines of chemotherapy for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

Time that passes before first appearance of Opportunistic Autoimmunity Secondary to cancer Immunotherapy. The baseline is the onset of cancer immunotherapy.

Pre-existing autoimmune disease will be defined by expert judgement on history of autoimmunity ongoing activity and blood analysis (preexisting autoantibodies will be investigated using biobanked serum)

Assessment of the prevalence of preexisting autoantibodies before immune checkpoint inhibitor initiation for the two groups of patients (one who develop severe autoimmune manifestations, one who does not develop severe autoimmune manifestations)

EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission	NCT06125457	COVID-19		18 Years -	University Hospital, Strasbourg, France
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission	NCT06125457	COVID-19		18 Years -	University Hospital, Strasbourg, France
Patient-Reported AutoImmunity Secondary to Cancer immunothErapy	NCT03849131	Opportunistic A...	Biological coll...	18 Years -	University Hospital, Strasbourg, France

Spots Global Cancer Trial Database for autoimmune manifestations